Five to buy
AstraZeneca
Pharmaceuticals giant AstraZeneca has spent the last ten years slimming down its “previously disparate drug portfolio” and increasing investment in research and development, which now comprises 20% of revenue each year. “The result has been... sales growth outstripping listed peers.” The company also boasts 13 “blockbuster” drugs generating at least $1bn in sales a year. While the patent for two of them will expire in 2025, it boasts a “meaty
